NZ594404A - Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof - Google Patents

Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Info

Publication number
NZ594404A
NZ594404A NZ594404A NZ59440409A NZ594404A NZ 594404 A NZ594404 A NZ 594404A NZ 594404 A NZ594404 A NZ 594404A NZ 59440409 A NZ59440409 A NZ 59440409A NZ 594404 A NZ594404 A NZ 594404A
Authority
NZ
New Zealand
Prior art keywords
ylmethoxy
pyrimidin
piperidin
oxo
benzyl
Prior art date
Application number
NZ594404A
Other languages
English (en)
Inventor
Axel Becker
Clemens Kuehn
Christoph Saal
Oliver Schadt
Dieter Dorsch
Heinz-Hermann Bokel
Frank Stieber
Christina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ594404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NZ594404A publication Critical patent/NZ594404A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
NZ594404A 2009-01-08 2009-12-04 Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof NZ594404A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09000140 2009-01-08
PCT/EP2009/008684 WO2010078897A1 (en) 2009-01-08 2009-12-04 Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Publications (1)

Publication Number Publication Date
NZ594404A true NZ594404A (en) 2013-04-26

Family

ID=41572530

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594404A NZ594404A (en) 2009-01-08 2009-12-04 Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Country Status (32)

Country Link
US (3) US8710058B2 (xx)
EP (1) EP2373640B1 (xx)
JP (2) JP5719781B2 (xx)
KR (2) KR101829595B1 (xx)
CN (1) CN102272121B (xx)
AR (1) AR074996A1 (xx)
AU (1) AU2009336839B2 (xx)
BR (1) BRPI0922642B8 (xx)
CA (4) CA2949515C (xx)
CL (1) CL2011001356A1 (xx)
CO (1) CO6400191A2 (xx)
CY (1) CY1115631T1 (xx)
DK (1) DK2373640T3 (xx)
EA (1) EA019342B1 (xx)
EC (1) ECSP11011248A (xx)
ES (1) ES2522629T3 (xx)
HK (1) HK1164856A1 (xx)
HR (1) HRP20140908T1 (xx)
IL (1) IL213829A0 (xx)
MX (3) MX363848B (xx)
MY (1) MY160017A (xx)
NZ (1) NZ594404A (xx)
PE (2) PE20141317A1 (xx)
PL (1) PL2373640T3 (xx)
PT (1) PT2373640E (xx)
SG (2) SG172831A1 (xx)
SI (1) SI2373640T1 (xx)
SM (1) SMT201400161B (xx)
TW (1) TWI475997B (xx)
UA (1) UA106220C2 (xx)
WO (1) WO2010078897A1 (xx)
ZA (1) ZA201105782B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949515C (en) * 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
US20150044211A1 (en) * 2012-03-19 2015-02-12 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
CN104768553A (zh) * 2012-11-02 2015-07-08 默克专利股份公司 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物
KR20160099724A (ko) * 2014-01-07 2016-08-22 메르크 파텐트 게엠베하 신장 세포 암종 (rcc) 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체
WO2016091346A1 (en) 2014-12-12 2016-06-16 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
WO2016155655A1 (zh) * 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
WO2016192831A1 (en) 2015-05-29 2016-12-08 Merck Patent Gmbh Compositions of anions and cations with pharmacological activity
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EA039713B1 (ru) * 2018-04-26 2022-03-03 Фуцзянь Косантер Фармасьютикал Ко., Лтд. Кристаллическая форма ингибитора c-met, его солевая форма и способ их получения
LT3996688T (lt) * 2019-07-10 2023-12-27 Merck Patent Gmbh Farmacinis preparatas
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
KR102489160B1 (ko) 2021-05-26 2023-01-18 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
WO2022250350A1 (ko) 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
EP4346829A1 (en) 2021-06-04 2024-04-10 Merck Patent GmbH Compounds for the treatment of glioblastoma
CN114394957B (zh) * 2021-12-24 2023-05-09 武汉九州钰民医药科技有限公司 Met抑制剂盐酸特泊替尼的制备方法
KR20230155324A (ko) 2022-05-03 2023-11-10 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169932B2 (en) * 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
DK1658079T3 (da) * 2003-08-19 2012-07-23 Pharmaton Sa Multivitaminsirup til børn eller unge voksne
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
CA2583152A1 (en) * 2004-10-21 2006-04-27 Pfizer Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
RU2007116107A (ru) * 2004-11-02 2008-11-10 Пфайзер Инк. (US) Способы получения индазольных соединений
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
US7846929B2 (en) * 2006-04-26 2010-12-07 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2949515C (en) * 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
TW201029655A (en) 2010-08-16
KR20170047408A (ko) 2017-05-04
MX2011007322A (es) 2011-07-29
EA201101039A1 (ru) 2012-02-28
CA2749012A1 (en) 2010-07-15
BRPI0922642B8 (pt) 2021-05-25
CN102272121A (zh) 2011-12-07
AU2009336839B2 (en) 2015-12-24
MX363848B (es) 2019-04-05
EP2373640B1 (en) 2014-07-30
CL2011001356A1 (es) 2011-09-30
BRPI0922642B1 (pt) 2020-09-29
DK2373640T3 (da) 2014-10-06
JP5719781B2 (ja) 2015-05-20
AU2009336839A8 (en) 2011-09-08
IL213829A0 (en) 2011-07-31
MX363852B (es) 2019-04-05
US9289427B2 (en) 2016-03-22
AU2009336839A1 (en) 2011-08-25
CN102272121B (zh) 2014-12-10
HK1164856A1 (en) 2012-09-28
MX350894B (es) 2017-09-22
KR101829595B1 (ko) 2018-02-14
UA106220C2 (ru) 2014-08-11
WO2010078897A1 (en) 2010-07-15
PE20141317A1 (es) 2014-09-26
CO6400191A2 (es) 2012-03-15
TWI475997B (zh) 2015-03-11
CY1115631T1 (el) 2017-01-04
JP2015038148A (ja) 2015-02-26
CA2749012C (en) 2017-01-31
PT2373640E (pt) 2014-09-30
JP5860126B2 (ja) 2016-02-16
CA3014648C (en) 2021-06-01
EA019342B1 (ru) 2014-02-28
CA2949515A1 (en) 2010-07-15
US20110269767A1 (en) 2011-11-03
SI2373640T1 (sl) 2014-11-28
US8710058B2 (en) 2014-04-29
AR074996A1 (es) 2011-03-02
PL2373640T3 (pl) 2014-12-31
SG172831A1 (en) 2011-08-29
PE20120474A1 (es) 2012-05-04
KR101730791B1 (ko) 2017-04-27
ECSP11011248A (es) 2011-10-31
CA3014648A1 (en) 2010-07-15
KR20110111472A (ko) 2011-10-11
ZA201105782B (en) 2012-04-25
MY160017A (en) 2017-02-15
SMT201400161B (it) 2015-01-15
EP2373640A1 (en) 2011-10-12
US20150148351A1 (en) 2015-05-28
JP2012514609A (ja) 2012-06-28
HRP20140908T1 (hr) 2014-11-07
BRPI0922642A2 (pt) 2016-01-05
US9308205B2 (en) 2016-04-12
CA3097370A1 (en) 2010-07-15
ES2522629T3 (es) 2014-11-17
SG10201504735QA (en) 2015-07-30
US20140200221A1 (en) 2014-07-17
CA2949515C (en) 2018-10-23

Similar Documents

Publication Publication Date Title
NZ594404A (en) Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
NZ610104A (en) Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
MY145616A (en) Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
PT2076501E (pt) Formas cristalinas do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzóico
NZ597511A (en) Diazahomoadamantane derivatives and methods of use thereof
NZ601644A (en) Cyclopropyl amine derivatives
NZ588612A (en) Benzothiophen derivatives as activators of peroxisome proliferator activated receptor (PPAR)
MY162440A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
NZ595797A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
EA201071299A1 (ru) 5-[5-[2-(3,5-бис(трифторметил)фенил)-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил-2-алкилпролинамиды в качестве антагонистов рецептора nk1
FR2936513B1 (fr) Procede de fabrication d'un derive, d'un hydrate ou d'un oxyde de zirconium
PE20120016A1 (es) Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion
CA2890273C (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
MX2009010861A (es) Oxazolidinonas para el tratamiento y la prevencion de hipertension pulmonar.
CL2009001088A1 (es) Forma cristalina (ii) de (1r,4r)-4-(1,1-dimetiletilsulfonamido)-n-(5-(trifluorometil) piridin-2-il) ciclohexancarboxamida; procesos de preparacion; utiles como antagonistas del receptor npyy5.
TH108525A (th) รูปพหุสัณฐานชนิดใหม่ของเกลือไฮโดรคลอไรด์ของ 3-(1-{3-[5-(1-เมธิล-พิเพอริดิน-4-อิลเมธอกซิ)-พิริมิดิน-2-อิล]-เบนซิล}-6-ออกโซ-1,6-ไดไฮโดร-พิริดาซิน-3-อิล)-เบนโซไนไทรล์ และกรรมวิธีการผลิตพวกมัน
UA44044U (ru) Способ обработки кожи
TH108525B (th) รูปพหุสัณฐานชนิดใหม่ของเกลือไฮโดรคลอไรด์ของ 3-(1-{3-[5-(1-เมธิล-พิเพอริดิน-4-อิลเมธอกซิ)-พิริมิดิน-2-อิล]-เบนซิล}-6-ออกโซ-1,6-ไดไฮโดร-พิริดาซิน-3-อิล)-เบนโซไนไทรล์ และกรรมวิธีการผลิตพวกมัน
IL210924A0 (en) A new crystalline form of 4-(5-{(ir)-1-[5-(3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine
UA29160U (ru) Устройство для изготовления штапельного волокна из горных пород

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: NOVEL POLYMORPHIC FORMS OF 3-(1-(3-(5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL)-BENZYL)-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF; FILING DATE: 04 AUG 2011; STATUS: REJECTED; TITLE: NOVEL POLYMORPHIC FORMS OF 3-(1-(3-(5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL)-BENZYL)-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF; FILING DATE: 04 AUG 2011; STATUS: REJECTED; TITLE: NOVEL POLYMORPHIC FORMS OF 3-(1-(3-(5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL)-BENZYL)-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT

Effective date: 20130419

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 DEC 2016 BY CPA GLOBAL

Effective date: 20131018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2017 BY CPA GLOBAL

Effective date: 20161021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2018 BY CPA GLOBAL

Effective date: 20171019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2019 BY CPA GLOBAL

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2020 BY CPA GLOBAL

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2021 BY CPA GLOBAL

Effective date: 20201022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2022 BY CPA GLOBAL

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2023 BY CPA GLOBAL

Effective date: 20221020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2024 BY CPA GLOBAL

Effective date: 20231019